Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


TGFβ Programs Central Memory Differentiation in Ex Vivo-Stimulated Human T Cells.

Dahmani A, Janelle V, Carli C, Richaud M, Lamarche C, Khalili M, Goupil M, Bezverbnaya K, Bramson JL, Delisle JS.

Cancer Immunol Res. 2019 Sep;7(9):1426-1439. doi: 10.1158/2326-6066.CIR-18-0691. Epub 2019 Jul 15.


The Bumpy Road to CAR Activation.

Janelle V.

Mol Ther. 2019 Jan 2;27(1):14-16. doi: 10.1016/j.ymthe.2018.12.003. Epub 2018 Dec 13. No abstract available.


Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers.

Granados DP, Rodenbrock A, Laverdure JP, Côté C, Caron-Lizotte O, Carli C, Pearson H, Janelle V, Durette C, Bonneil E, Roy DC, Delisle JS, Lemieux S, Thibault P, Perreault C.

Leukemia. 2016 Jun;30(6):1344-54. doi: 10.1038/leu.2016.22. Epub 2016 Feb 9.


Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture.

Janelle V, Carli C, Taillefer J, Orio J, Delisle JS.

J Transl Med. 2015 Apr 19;13:123. doi: 10.1186/s12967-015-0495-z.


Expression of Viral Antigen by the Liver Leads to Chronic Infection Through the Generation of Regulatory T Cells.

Lapierre P, Janelle V, Langlois MP, Tarrab E, Charpentier T, Lamarre A.

Cell Mol Gastroenterol Hepatol. 2015 Feb 24;1(3):325-341.e1. doi: 10.1016/j.jcmgh.2015.02.002. eCollection 2015 May.


Early exposure to interleukin-21 limits rapidly generated anti-Epstein-Barr virus T-cell line differentiation.

Orio J, Carli C, Janelle V, Giroux M, Taillefer J, Goupil M, Richaud M, Roy DC, Delisle JS.

Cytotherapy. 2015 Apr;17(4):496-508. doi: 10.1016/j.jcyt.2014.12.009. Epub 2015 Feb 3.


How Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity?

Janelle V, Lamarre A.

Front Oncol. 2014 Jun 4;4:135. doi: 10.3389/fonc.2014.00135. eCollection 2014. No abstract available.


Role of the complement system in NK cell-mediated antitumor T-cell responses.

Janelle V, Lamarre A.

Oncoimmunology. 2014 Jan 1;3(1):e27897. Epub 2014 Feb 14.


Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells.

Janelle V, Langlois MP, Tarrab E, Lapierre P, Poliquin L, Lamarre A.

Cancer Immunol Res. 2014 Mar;2(3):200-6. doi: 10.1158/2326-6066.CIR-13-0173. Epub 2013 Dec 5.


The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.

Janelle V, Langlois MP, Lapierre P, Charpentier T, Poliquin L, Lamarre A.

Mol Ther. 2014 Jun;22(6):1198-1210. doi: 10.1038/mt.2014.34. Epub 2014 Mar 4.


Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity.

Goulet ML, Olagnier D, Xu Z, Paz S, Belgnaoui SM, Lafferty EI, Janelle V, Arguello M, Paquet M, Ghneim K, Richards S, Smith A, Wilkinson P, Cameron M, Kalinke U, Qureshi S, Lamarre A, Haddad EK, Sekaly RP, Peri S, Balachandran S, Lin R, Hiscott J.

PLoS Pathog. 2013;9(4):e1003298. doi: 10.1371/journal.ppat.1003298. Epub 2013 Apr 25. Erratum in: PLoS Pathog. 2013 Aug 8;9(8):.


[Vesicular stomatitis virus in the fight against cancer].

Janelle V, Poliquin L, Lamarre A.

Med Sci (Paris). 2013 Feb;29(2):175-82. doi: 10.1051/medsci/2013292015. Epub 2013 Feb 28. Review. French.


Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.

Janelle V, Brassard F, Lapierre P, Lamarre A, Poliquin L.

J Virol. 2011 Jul;85(13):6513-20. doi: 10.1128/JVI.02484-10. Epub 2011 May 11.

Supplemental Content

Loading ...
Support Center